BEQVEZ is an FDA-approved, one-time gene therapy infusion for eligible adults with moderate to severe hemophilia B
Tim, an actual BEQVEZTM (fidanacogene elaparvovec- dzkt) patient, playing the guitar with the words "this is me living with hemophilia differently". Tim, an actual BEQVEZTM (fidanacogene elaparvovec- dzkt) patient, playing the guitar with the words "this is me living with hemophilia differently".
style
No-padding

Tim, who received the BEQVEZ infusion in 2021.*

*Tim participated in the BEQVEZ clinical study. He was compensated for sharing his story. His words and opinions are his own. BEQVEZ is not approved for use in females.

Check out Tim’s full story
style
No-padding
A one-time BEQVEZ infusion†:

Offers a chance of bleed protection without the need for factor IX prophylaxis (FIX prophy)

Known safety profile, studied since 2017

Pfizer has over 25 years of commitment to the hemophilia community

†Individual results and duration of effect may vary. The main BEQVEZ study is ongoing to assess the long-term efficacy and safety of BEQVEZ. On-demand FIX may still be required.

Bar graph in magnifying glass

Discover the data for BEQVEZ

Learn more

DNA icon blue

See how BEQVEZ works

Find out more

Bill, an actual BEQVEZTM (fidanacogene elaparvovec-dzkt) patient, in a workshop

Watch stories from real BEQVEZ patients

Check out real stories

style
No-padding
prev-page
next-page
Why gene therapy?